1010802-00-2

Basic information

• Product Name: C₂₉H₂₉F₅N₆O₄
• Synonyms: C₂₉H₂₉F₅N₆O₄
• CAS NO: 1010802-00-2
• Molecular Weight: 620.579
• Mol File: 1010802-00-2.mol

Chemical Properties

• CAS DataBase Reference: C₂₉H₂₉F₅N₆O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₉H₂₉F₅N₆O₄(1010802-00-2)
• EPA Substance Registry System: C₂₉H₂₉F₅N₆O₄(1010802-00-2)

Safety Data

• Hazardous Substances Data: 1010802-00-2(Hazardous Substances Data)

Upstream product

• 749230-30-6 (2,3-difluorophenoxy)triisopropylsilane 
• 6418-38-8 2,3-difluorophenol 
• 1010800-88-0 2,3-difluoro-4-((triisopropylsilyl)oxy)benzoic acid 
• 1010801-00-9 2,3-difluoro-4-((triisopropylsilyl)oxy)benzaldehyde 
• 256417-11-5 2,3-difluoro-4-methoxy-benzaldehyde 
• 676500-39-3 2,3-difluoro-4-hydroxybenzaldehyde 
• 1010801-01-0 methyl 3-(2,3-difluoro-4-methoxyphenyl)-3-hydroxy-2,2-dimethylpropanoate 
• 1010801-02-1 methyl 3-(2,3-difluoro-4-methoxyphenyl)-2,2-dimethyl-3-oxopropanoate 
• 1010801-04-3 3-(2,3-difluoro-4-hydroxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one 
• 1010801-66-7 2-(4-bromobutyl)-6-(7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one 
• 1010801-03-2 5-(2,3-Difluoro-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydropyrazol-3-one 
• 909719-71-7 6-[7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone 

Relevant articles and documents

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.